eIF4E Inhibitor Compounds for Cap-Dependent Translation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dysregulated eIF4E is implicated in various disorders, particularly cancer, and existing treatments lack effective inhibitors to target this protein for therapeutic intervention.
Innovation Solution
Development of compounds that inhibit eIF4E activity, specifically those conforming to Formula (I) or their pharmaceutically acceptable salts, which can be used to treat diseases associated with eIF4E, such as cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used, then current therapeutic options are available, but effective inhibition of eIF4E activity is not achieved
Solution Approach 1:
The patent segments the eIF4E protein structure into specific binding regions and develops compounds that target distinct functional domains. The compounds are designed to bind to specific regions of eIF4E (such as the cap-binding region or the interface with eIF4G) to achieve selective inhibition of eIF4E-mediated translation while preserving other cellular functions.
Solution Approach 2:
The patent introduces small molecule compounds as intermediary substances that mediate between the eIF4E protein and its substrates. These compounds act as molecular intermediaries that block the interaction between eIF4E and the 7-methylguanosine cap structure, thereby preventing cap-dependent translation initiation without directly modifying the eIF4E protein structure.
2Adaptability or versatility
If eIF4E is targeted for therapeutic intervention, then potential treatment for cancer and other disorders is achieved, but no effective inhibitors exist
Solution Approach 1:
The patent systematically varies key parameters of the compound structure including the core scaffold type, substituent groups, molecular weight, hydrophobicity, and binding affinity. By optimizing these parameters, the invention achieves compounds with appropriate pharmacokinetic properties, selective eIF4E binding, and therapeutic efficacy across multiple disease models including cancer and viral infections.
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional elements: a core binding scaffold, specific substituent groups for enhanced affinity, and pharmacophoric features for selective eIF4E interaction. These composite compounds integrate multiple functional properties into a single molecular entity to achieve both high specificity and therapeutic effectiveness.
3Reliability
If compounds conforming to Formula (I) are developed, then eIF4E inhibition is achieved, but complexity of compound structure increases
Solution Approach 1:
The patent extracts and isolates the essential binding elements required for eIF4E inhibition from complex molecular structures. The compounds are designed to contain only the necessary pharmacophoric features for eIF4E binding, removing unnecessary structural complexity while maintaining high inhibition activity. This includes identifying minimal structural requirements for cap-binding region interaction.
Solution Approach 2:
The patent applies local quality by concentrating functional groups and structural features specifically at the regions of the molecule that interact with eIF4E binding sites. Rather than uniformly complex structures throughout, the compounds have localized areas of high functional density at the binding interface, with simpler regions elsewhere in the molecule.
Data Source
AI summary
The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.